LIXTE BIOTECHNOLOGY HOLDINGS (LIXT) 0.79 -0.05 (-5.95%)
0.79 -0.05 (-5.95%)
US5393192027 - Common Stock - After market: 0.7505 -0.04 (-5%)
LIXTE BIOTECHNOLOGY HOLDINGS REPORTS NEWLY PUBLISHED INDEPENDENT PRE-CLINICAL RESEARCH
THE RESEARCH SHOWS THAT PP2A, THE TARGET OF LIXTE’S LEAD CLINICAL COMPOUND, LB-100, WHEN DEFICIENT, ENHANCES EFFECTS OF IMMUNE CHECKPOINT BLOCKADE OF...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to keep a watch on Monday!
CRWD Stock Alert: What to Know About CrowdStrike’s New President
CrowdStrike (CRWD) stock is in the news Wednesday as the cybersecurity company announced Michael Sentonas as its new president.
Tripadvisor (TRIP) Stock Receives Double Upgrade From Bank of America
Tripadvisor (TRIP) stock is getting a boost on Wednesday after the company got a double upgrade and new price target from Bank of America.
BABA Stock Alert: Alibaba Tests AI Tool to Compete With ChatGPT
Alibaba (BABA) stock is on the move Wednesday as investors react to news of the company testing an AI tool to rival ChatGPT.
Why Is Lixte Biotech (LIXT) Stock Down 29% Today?
Lixte Biotech (LIXT) stock is dropping on Wednesday but it's not due to any negative news from the drug discovery company.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Our coverage starts today with a look at the biggest pre-market stock movers traders will want to keep an eye on Wednesday!
LIXTE BIOTECHNOLOGY HOLDINGS, INC. REPORTS THAT ITS LEAD CLINICAL COMPOUND, LB-100, CAN KILL CANCER CELLS THROUGH HYPER-STIMULATION OF CELL PROLIFERATION SIGNALS IN PRE-CLINICAL MODELS
--THE STUDY ESTABLISHES A NOVEL CONCEPT OF “TUMOR SUPPRESSIVE DRUG RESISTANCE” --THE COMBINATION OF LB-100 WITH INHIBITORS OF CELLULAR STRESS RESPONSE...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday morning!
LIXTE BIOTECHNOLOGY ANNOUNCES APPROVAL OF A PHASE 1B/2 RANDOMIZED TRIAL OF DOXORUBICIN +/-LB-100 IN ADVANCED SOFT TISSUE SARCOMAS TO BE CONDUCTED BY THE SPANISH SARCOMA GROUP
PASADENA, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), (“LIXTE” or the “Company”), a clinical-stage...
